当前位置： SCI文献检索 > Journal of Biopharmaceutical Statistics期刊下所有文献 > Test procedures for disease prevalence with partially validated data.

Test procedures for disease prevalence with partially validated data.

Abstract：

:Investigating the prevalence of a disease is an important topic in medical studies. Such investigations are usually based on the classification results of a group of subjects according to whether they have the disease. To classify subjects, screening tests that are inexpensive and nonintrusive to the test subjects are frequently used to produce results in a timely manner. However, such screening tests may suffer from high levels of misclassification. Although it is often possible to design a gold-standard test or device that is not subject to misclassification, such devices are usually costly and time-consuming, and in some cases intrusive to the test subjects. As a compromise between these two approaches, it is possible to use data that are obtained by the method of double-sampling. In this article, we derive and investigate four test statistics for testing a hypothesis on disease prevalence with double-sampling data. The test statistics are implemented through both the asymptotic method suitable for large samples and approximate unconditional method suitable for small samples. Our simulation results show that the approximate unconditional method usually produces a more satisfactory empirical type I error rate and power than its asymptotic counterpart, especially for small to moderate sample sizes. The results also suggest that the score test and the Wald test based on an estimate of variance with parameters estimated under the null hypothesis outperform the others. An real example is used to illustrate the proposed methods.

journal_name

J Biopharm Stat

journal_title

Journal of biopharmaceutical statistics

authors

Tang ML,Qiu SF,Poon WY,Tang NS

doi

10.1080/10543406.2010.544527

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

368-86

issue

2

eissn

1054-3406

issn

1520-5711

journal_volume

22

pub_type

杂志文章

相关文献

Journal of Biopharmaceutical Statistics文献大全
  • On sample size calculation based on odds ratio in clinical trials.

    abstract：:Sample size calculation formulas for testing equality, noninferiority, superiority, and equivalence based on odds ratio were derived under both parallel and one-arm crossover designs. An example concerning the study of odds ratio between a test compound (treatment) and a standard therapy (control) for prevention of re...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-120016231

    authors： Wang H,Chow SC,Li G

    更新日期：2002-11-01 00:00:00

  • Balancing statistical and ethical considerations in planning clinical trials: recommendations for response-adaptive randomization urn designs.

    abstract：:During a clinical trial, balancing statistical and ethical considerations are important. Response-adaptive randomization methods use the information from past patients to increase the probability of the next patient receiving the better treatment while avoiding the statistical concern of selection bias. We compared th...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2018.1437172

    authors： Piccorelli AV,Fraker SA

    更新日期：2018-01-01 00:00:00

  • Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

    abstract：:I review the designs available for Phase I dose-finding studies of chemotherapeutic agents in cancer patients. The designs are based on the assumption that both efficacy and toxicity increase with dose, and thus attempt to minimize the number of patients treated at low doses, and also to minimize the chance that patie...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543400600860295

    authors： Potter DM

    更新日期：2006-01-01 00:00:00

  • The analysis, interpretation, and presentation of quality of life data.

    abstract：:All too often in clinical trials the assessment of quality of life is seen as a bolt-on study. Consequently insufficient consideration is often given to its design, collection, analysis and presentation, and its impact on the trial results and on clinical practice is minimal. In many trials quality of life is a key en...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-120028506

    authors： Stephens R

    更新日期：2004-02-01 00:00:00

  • A useful testing strategy in phase III trials: combined test of superiority and test of equivalence.

    abstract：:A useful testing strategy is proposed for a confirmatory phase III clinical trial. It consists of a combined test of superiority and test of equivalence, and it is easy to apply. By introducing the strategy, we can perform a post hoc analysis in a confirmatory experiment. Thus a more flexible decision will be possible...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409508835115

    authors： Morikawa T,Yoshida M

    更新日期：1995-11-01 00:00:00

  • Bayesian statistics in medical devices: innovation sparked by the FDA.

    abstract：:Bayesian statistical methodology has been used for more than 10 years in medical device premarket submissions to the U.S. Food and Drug Administration (FDA). A complete list of the publicly available information associated with these FDA applications is presented. In addition to the increasing number of Bayesian metho...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2011.589638

    authors： Campbell G

    更新日期：2011-09-01 00:00:00

  • Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.

    abstract：:This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems a...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2014.1000546

    authors： Abel UR,Jensen K,Karapanagiotou-Schenkel I,Kieser M

    更新日期：2015-01-01 00:00:00

  • Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.

    abstract：:A new three-arm parallel design was recently proposed to investigate the biosimilarity between a biological product and a reference product by using the relative distance. The purpose of this article is to extend their results to binary endpoints for three popular metrics: the risk difference, the log relative risk, a...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2014.979195

    authors： Shin W,Kang SH

    更新日期：2016-01-01 00:00:00

  • Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

    abstract：:In this article, a parametric sequential test is proposed under the Weibull model. The proposed test is asymptotically normal with an independent increment structure. The sample size for a fixed sample test is derived for the purpose of group sequential trial design. In addition, a multi-stage group sequential procedu...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2014.971165

    authors： Wu J,Xiong X

    更新日期：2015-01-01 00:00:00

  • Bayesian pooling versus sequential integration of small preclinical trials: a comparison within linear and nonlinear modeling frameworks.

    abstract：:Bayesian sequential integration is an appealing approach in drug development, as it allows to recursively update posterior distributions as soon as new data become available, thus considerably reducing the computation time. However, preclinical trials are often characterized by small sample sizes, which may affect the...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2020.1776312

    authors： La Gamba F,Jacobs T,Serroyen J,Geys H,Faes C

    更新日期：2020-06-18 00:00:00

  • Designing studies to find early signals of efficacy.

    abstract：:We introduce the idea of a design to detect signals of efficacy in early phase clinical trials. Such a design features three possible decisions: to kill the compound; to continue with staged development; or to continue with accelerated development of the compound. We describe how such studies improve the trade-off bet...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2011.570466

    authors： Brown MJ,Chuang-Stein C,Kirby S

    更新日期：2012-01-01 00:00:00

  • A multilevel model for hierarchical, repeated, and overdispersed time-to-event outcomes and its estimation strategies.

    abstract：:The aim of this article is to propose a multilevel combined model for repeated, hierarchical, and overdispersed time-to-event outcomes, extending the so-called combined model proposed by Molenberghs et al. (2010), and using three different estimation strategies: full likelihood, pseudo-likelihood, and Bayesian estimat...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2013.834914

    authors： Efendi A,Molenberghs G

    更新日期：2013-01-01 00:00:00

  • Planning survival studies to compare a treatment to an active control.

    abstract：:Rubinstein et al. presented a procedure for determining the required duration of accrual for a clinical trial comparing the survival distributions of two treatments using a classical hypothesis testing formulation. Here their testing procedure is modified in two ways. First, the asymptotic variances used in computatio...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409308835056

    authors： Bristol DR

    更新日期：1993-09-01 00:00:00

  • Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

    abstract：:Frequentist design for two-arm randomized Phase II clinical trials with outcomes from the exponential dispersion family was proposed previously, where the total sample sizes are minimized under multiple constraints on the standard errors of the estimated group means and their difference. This design was generalized fr...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2017.1402779

    authors： Jiang W,Wick JA,He J,Mahnken JD,Mayo MS

    更新日期：2018-01-01 00:00:00

  • Equivalence tests for shelf life and average drug content in stability studies.

    abstract：:Stability testing is a procedure frequently used in the pharmaceutical industry to estimate the shelf life of a drug. Hereby, a standard problem of interest is whether or not to pool a given number of batches to assign a single shelf life for the combined batches. In this paper, we propose two modified methods for the...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543400802287230

    authors： Djira GD,Hothorn LA,Tsong Y

    更新日期：2008-01-01 00:00:00

  • Confidence interval of the difference between two proportions with overdispersion.

    abstract：:In confidence interval estimation of the difference between two proportions with overdispersion due to positive correlations, the usual asymptotic normality-based method generally has lower coverage rates than desired, especially when sample size is moderate. Applying the concept of effective sample size to existing m...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-120037193

    authors： Chen C,Li J,Zhou Z

    更新日期：2004-05-01 00:00:00

  • Statistical considerations in setting product specifications.

    abstract：:According to ICH Q6A (1999), a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. For drug products, specifications usually consist of test methods and acceptance criteria ...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2014.972511

    authors： Dong X,Tsong Y,Shen M

    更新日期：2015-01-01 00:00:00

  • Subgroup analyses in randomized clinical trials: statistical and regulatory issues.

    abstract：:Recently, two CPMP Points to Consider, one on adjustment for baseline covariates and the other on multiplicity issues in clinical trials, have included recommendations on the use of subgroup analysis for regulatory purposes. However, despite their regular use and regulatory attention, the validity and nature of subgro...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-200067988

    authors： Grouin JM,Coste M,Lewis J

    更新日期：2005-01-01 00:00:00

  • Modeling anti-KLH ELISA data using two-stage and mixed effects models in support of immunotoxicological studies.

    abstract：:During preclinical drug development, the immune system is specifically evaluated after prolonged treatment with drug candidates, because the immune system may be an important target system. The response of antibodies against a T-cell-dependent antigen is recommenced by the FDA and EMEA for the evaluation of immunosupp...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：

    authors： Shkedy Z,Straetemans R,Molenberghs G,Desmidt M,Vinken P,Goeminne N,Coussement W,Van Den Poel B,Bijnens L

    更新日期：2005-01-01 00:00:00

  • Design and sample size considerations for simultaneous global drug development program.

    abstract：:Due to the potential impact of ethnic factors on clinical outcomes, the global registration of a new treatment is challenging. China and Japan often require local trials in addition to a multiregional clinical trial (MRCT) to support the efficacy and safety claim of the treatment. The impact of ethnic factors on the t...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章,评审

    doi：10.1080/10543406.2012.701587

    authors： Huang Q,Chen G,Yuan Z,Lan KK

    更新日期：2012-09-01 00:00:00

  • Dose-time-response modeling using negative binomial distribution.

    abstract：:People exposed to certain diseases are required to be treated with a safe and effective dose level of a drug. In epidemiological studies to find out an effective dose level, different dose levels are applied to the exposed and a certain number of cures is observed. Negative binomial distribution is considered to fit o...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2013.834916

    authors： Roy M,Choudhury K,Islam MM,Matin MA

    更新日期：2013-01-01 00:00:00

  • A group sequential approach to crossover trials for average bioequivalence.

    abstract：:Group sequential methods to allow the possibility of early termination of a trial due to sufficiently convincing results are a standard in therapeutic clinical trials but have been little considered in bioequivalence trials. We investigate the statistical properties of one group sequential approach to bioequivalence t...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409708835171

    authors： Hauck WW,Preston PE,Bois FY

    更新日期：1997-03-01 00:00:00

  • Innovative Thinking on Endpoint Selection in Clinical Trials.

    abstract：:In clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the t...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2019.1657140

    authors： Chow SC,Huang Z

    更新日期：2019-01-01 00:00:00

  • Power and sample size for the S:T repeated measures design combined with a linear mixed-effects model allowing for missing data.

    abstract：:Tango (Biostatistics 2016) proposed a new repeated measures design called the S:T repeated measures design, combined with generalized linear mixed-effects models and sample size calculations for a test of the average treatment effect that depend not only on the number of subjects but on the number of repeated measures...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2017.1293083

    authors： Tango T

    更新日期：2017-01-01 00:00:00

  • Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

    abstract：:A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we prop...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2016.1226324

    authors： Li JX,Chen WC,Scott JA

    更新日期：2016-01-01 00:00:00

  • Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.

    abstract：:To confirm results obtained from local evaluation at investigational centers, many oncology studies utilize blinded independent central review (BICR) to make assessments of the primary endpoint, progression-free survival (PFS). The comparison of data often leads to large discordances between these observations, castin...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2013.813516

    authors： Mannino FV,Amit O,Lahiri S

    更新日期：2013-01-01 00:00:00

  • An equivalence test for the comparison between a test drug and placebo in human abuse potential studies.

    abstract：:Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-related measures using volunteers with histories of recreational drug use. These studies typically have a randomized, dou...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543406.2011.616972

    authors： Chen L,Bonson KR

    更新日期：2013-03-11 00:00:00

  • Factorial dose-response studies using frequency and magnitude of dose.

    abstract：:In the early stages of traditional drug development, the frequency of dosing (e.g., QD, BID, etc.) is typically determined by the pharmacokinetic properties of a compound. After an appropriate dose frequency is chosen, the magnitude of dose is then evaluated via parallel-group dose-response trials. For some drugs, how...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543409608835141

    authors： Hafner KB,Ruberg SJ

    更新日期：1996-07-01 00:00:00

  • Use of predictive probabilities in phase II and phase III clinical trials.

    abstract：:Predictive probability is particularly useful in aiding a decision-making process related to drug development. This is especially true for decisions occurring as the result of interim analyses of clinical trials. Examples of clinical trial applications of Bayesian predictive probability and the use of the beta-binomia...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1081/BIP-100101000

    authors： Johns D,Andersen JS

    更新日期：1999-03-01 00:00:00

  • Wilcoxon-Mann-Whitney test: stratify or not?

    abstract：:The Wilcoxon-Mann-Whitney (WMW) test is the most commonly used nonparametric method to compare two treatments when the underlying distribution of the outcome variable is not normally distributed. In the presence of stratum effects, the van Elteren (vE) test, a stratified WMW test, can be used to adjust for the stratum...

    journal_title：Journal of biopharmaceutical statistics

    pub_type： 杂志文章

    doi：10.1080/10543400802369103

    authors： Qu Y,Zhao YD,Rahardja D

    更新日期：2008-01-01 00:00:00